A six-year Japanese post-marketing surveillance study reported sustained HIV suppression after patients switched to dolutegravir/rilpivirine. In the small assessed cohort, viral control remained stable and CD4+ T-cell counts were unchanged over the follow-up window, alongside only non-serious adverse events. The findings contribute real-world durability evidence for a two-drug regimen approach, which matters for patient adherence and tolerability in long-term management. The study also provides additional safety signals from routine clinical use beyond initial trials. For HIV stakeholders, the primary implication is confidence in regimen stability for virologically controlled patients, while continued monitoring will remain important as broader populations and longer exposure accumulate.